Table 1.
Patient demographics and baseline characteristics of randomized patients.
| T/HCTZ (n = 428) | V/HCTZ (n = 412) | |
| Gender (n [%]) | ||
| Men | 230 (53.7) | 239 (58.0) |
| Women | 198 (46.3) | 173 (42.0) |
| Age | ||
| Mean ± SD (years) | 58.5 ± 9.7 | 59.2 ± 9.7 |
| ≥ 65 years (n [%]) | 122 (28.5) | 119 (28.9) |
| Race (n [%]) | ||
| White | 292 (68.2) | 292 (70.9) |
| Black | 61 (14.3) | 59 (14.3) |
| Asian | 75 (17.5) | 61 (14.8) |
| BMI | ||
| Mean ± SD (kg/m2) | 33.6 ± 5.7 | 33.4 ± 5.3 |
| Hypertension duration | ||
| Mean ± SD (years) | 9.2 ± 9.5 | 8.9 ± 9.2 |
| 24-hour ABP | ||
| Mean SBP ± SD (mm Hg) | 148.0 ± 11.9 | 147.8 ± 12.4 |
| Mean DBP ± SD (mm Hg) | 83.1 ± 9.2 | 83.3 ± 10.2 |
| Trough seated BP | ||
| Mean SBP ± SD (mm Hg) | 156.8 ± 12.5 | 157.1 ± 12.3 |
| Mean DBP ± SD (mm Hg) | 92.1 ± 9.3 | 91.7 ± 9.8 |
| HbA1c (%) | ||
| Mean ± SD | 7.0 ± 1.1 | 7.2 ± 1.2 |
ABP: ambulatory blood pressure; DBP: diastolic blood pressure; T/HCTZ: telmisartan 80 mg plus HCTZ 12.5 mg; V/HCTZ; valsartan 160 mg plus HCTZ 12.5 mg; SBP: systolic blood pressure.